Pfizer Oncology: Big Strides But Not Blockbuster Size
Executive Summary
Pfizer’s emphasis on oncology has yielded three new drug approvals in the last 20 months and another two promising drugs on the horizon. It is a notable achievement, but investors may be wondering when the results are going to be felt on the top line.
You may also be interested in...
Deal Watch: Pfizer, BioAtla Team Up To Develop Targeted Antibody Oncologics
ViroMed looks to bluebird to take its humanized antibody to the next steps of development in immuno-oncology. Takeda gets option for Cour's nanoparticle technology in Celiac disease, as well as up to three other indications.
First-Line Breast Cancer Approval Opens The Door For Pfizer’s Palbociclib
The CDK 4/6 inhibitor Ibrance (palbocliclib) just got its first approval in first-line metastatic breast cancer and Pfizer is losing no time on development, with trials of other indications planned or ongoing, including different tumor types.
Pfizer’s Dolsten Explains Why The Big Pharma Can Win The Immuno-Oncology Marathon
Pfizer isn’t considered one of the frontrunners in the immuno-oncology race, but R&D President Mikael Dolsten declares the company, with five agents in the clinic in 2015, will be a force in the therapeutic area.